Vaccine progress is of enormous practical consequence. Effective reporting of material information can move markets, and that means it's useful for efficient capital allocation.

Of course, there's diminishing returns and problems with many kinds of noise, and AstraZenica isn't strongly interested in marginal efficiencies in the broader market.